Clinical outcome of treatment. (A) Swimmer plot showing the clinical response and follow-up of the individual patients, as denoted with different colors in the swimmer lanes. Each bar represents 1 patient. The indicated responses include a CR and a CMR. Before the systemic chemotherapies, imatinib was replaced with dasatinib for 2 patients. Patient 9, with no ABL mutations, had a poor response after 1 cycle of induction with imatinib but demonstrated a molecular response after reinduction with dasatinib. Patient 13 was intolerant of imatinib owing to severe rash and edema. (B) Treatment response at the end of induction therapy, each systemic therapy, and each cycle of CAR T-cell infusion. (C-D) Kaplan-Meier estimates of OS and RFS for the 15 patients who were included in the primary efficacy analysis.